PubMed Health⌕ Search

Biomedical subjects

I B Sorokina

Publications and source records attributed to I B Sorokina.

At least 19 recordsLinked to original sources
PubMed2003

[Experience with ixel (milnacipran hydrochloride) use in the treatment of patients with post-stroke depression].

AIM: To evaluate antidepressive efficacy of ixel in patients with poststroke depression (PSD). MATERIAL AND METHODS: The study included 59 PSD patients aged 43-79 years divided into two groups: the test group (31 patients) treated with antidepressive drugs and the control group (28 patients) was not treated with such drugs. The test group took a two-month treatment with oral ixel in a dose 100 mg/day. The neurological status was assessed by Lindmark scale (LS), severity of depression-by Hamilton scale (HS). RESULTS: On ixel treatment day 10-14 the patients felt better, by the treatment day 60 depression disappeared in 60.9%, only borderline conditions were seen in 39.1%. Mean score by HS fell from 15.8 to 5.7. The controls showed moderate reduction of some symptoms of depression, mean score by HS decreased insignificantly (from 14.5 to 13.4). By LS, significant differences between the groups were not registered. Side effects arose in 10 patients, 6 of them withdrew. CONCLUSION: Ixel is an effective drug against depression in stroke survivors.

Adult↗
PubMed2002

[Post-stroke depression: an experience in using cipramil].

Fifteen patients, 12 males, 3 females, aged 59.6 +/- 9.6 years, with depression after stroke, occurred 9 months--1 year and 3 months before, were treated with cipramil in dose 20 mg/day during 2.5 months. Control group comprised 10 patients matched for demographic and clinical characteristics and been not assigned to cipramil. All patients were fully examined by clinical methods, including computer tomography. Besides, for patient's state evaluation, Hamilton rating scale for depression and Lindmark scale for focal neurologic deficit measuring have been administered. The initial scores on these scales were 22.8 +/- 4.5 and 381.4 +/- 33.4 in the basic group and--22.2 +/- 6.3 and 390.6 +/- 29.8 in the controls, respectively. While cipramil using, an improvement was observed rather quickly--after 2-3 weeks, being stable during the whole treatment course. After treatment finishing, depression scores on Hamilton scale decreased to 15.8 +/- 5.2 (p < 0.001) in the basic group and did not change in the control one. The neurological deficit expression has not been changed. Side effects were mildly expressed in 20% of the patients. In one-third of the patients, antidepressant effect diminished in 1.5 months after treatment finishing. A need for longer antidepressant treatment of post stroke patients is discussed.

Antidepressive Agents, Tricyclic↗
PubMed2001

[Peculiarities of depressive syndrome in patients with ischemic stroke].

42 patients with post-stroke depression were investigated in the follow-up study in different periods after stroke. Hamilton scale was used for diagnosis and evaluation of depression. In such depression moderate somato-autonomic disorders predominated. The most prominent were dissomnia, general somatic symptoms and sexual dysfunction. There was no clear dependance between degree of depression and age of patients, lesion location and severity of focal neurological deficit. Symptoms of depression greatly influenced on cognitive functions.

Adult↗
PubMed1987

[Isolation and structure of the active component of the antitumor agent blastolysin].

Active principle of blastolysin, comprising ca. 40% of the total weight of Lactobacillus bulgaricus cell wall preparation, has been isolated and structurally studied by chemical and spectral methods. The substance a glycopeptide with Mr aa. 10,000, consists of two tetrasaccharide moieties connected by oligopeptide bridges; glycerophosphate, glucose, and galactose moieties are also attached to N-acetylmuramyl residue of the peptidoglucan core. Tetrasaccharide-containing muramylpeptides were shown to be responsible for the antitumour activity.

Amino Acid Sequence↗
PubMed1985

[Change in the natural immunity of mice after administration of blastolysin, a glycopeptide from the Lactobacillus bulgaricus cell wall].

The effect of blastolysin, a glycopeptide of the cell walls of L. bulgaricus, on the resistance of mice to infections caused by S. typhimurium and B. pertussis, lysozyme levels in the blood serum and 5'-nucleotidase activity of peritoneal macrophages was studied. The changes in the nonspecific resistance of mice due to the effect of blastolysin depended on the administration route and the type of the developing infection. It activated the enzymatic activity of the peritoneal macrophages and changed the lysozyme levels in the blood serum of mice. The optimal protective effect of blastolysin was achieved on intramuscular injection in a dose of 100 micrograms.

5'-Nucleotidase↗
PubMed1985

[Effect on human complement of blastolysin and the glycopeptide (MDP and GMDP) and carbohydrate fragments of peptidoglycans].

Along with complement activation by the classical pathway, blastolysin, an antitumor and adjuvant preparation of Lactobacillus bulgaricus peptidoglycans, effectively inhibits the transformation of C3 in to C5 convertase. Values of inhibition maximum and dissociation constants of the reversible C3b-acceptor complex for blastolysin and main immunological active structural moieties of peptidoglycans (GMDP, MDP) and their inactive carbohydrate components (N-acetylglucosaminyl-N-acetylmuramic acid, N-acetylglucosamine, and N-acetylmuramic acid) have been determined. Immunostimulator concentrations for blastolysin, GMDP, and MDP in inhibition of the C5 convertase formation (C3b binding) correlate with their doses in vivo (animal blood), displaying antitumor activity.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1980

[Macrophage activation by blastolysin].

Blastolysin consisting largely of glycopeptide fragments of cell walls from Lactobacillus bulgaricus has a significant antineoplastic activity against a number of transplanted and spontaneous animal tumours. Blastolysin exerts a pronounced adjuvant action and activates the cells of the mononuclear phagocytic system. This is shown by stimulation of phagocytosis and digestion as well as by acquired ability of macrophages to elicit a cytotoxic action on allogeneic and syngeneic target cells (labelled with radioactive chromium) with abnormal growth. Administration of blastolysin or BCG was demonstrated to lead to variations in the time course of macrophage acquired cytotoxicity. Macrophage activation induced by blastolysin has a clearly pronounced two-phasic nature. During the first short phase the cytotoxicity is seen 2 hours following blastolysin administration, rapidly disappears and emerges after 2 weeks, remaining unchanged up to the 5th week (experimental period).

Animals↗
PubMed1975

[Action of valinomycin in vivo on Ehrlich ascites tumor cells. A change in the ultrastructure of the tumor cells under the influence of valinomycin].

It was found with the help of electron microscopy that valinomycin administered to mice with Ehrlich ascitic tumors in a dose inhibiting the proliferating activity induced impairements in the mitochondria. The changes were similar to those under the effect of valinomycin in vitro. An increase in the antibiotic dose resulted in more pronounced and irreversible changes not only in the mitochondria but also in other structures of the tumor cells.

Animals↗
PubMed1975

[In vivo action of valinomycin on Ehrlich ascites tumor cells. Inhibition of the proliferative activity of the tumor cells under the action of valinomycin].

It was shown that repeated administrations of valinomycin in doses of 1.0 and 0.01 gamma/gm to mice with Ehrlich ascitic tumors inhibited the ascite development. The radioautographic study using 3H-thimidine showed that 24 hours after the administration of valinomycin in doses of 0.1 and 0.01 gamma/gm transference of the cells into the phase of DNA synthesis was inhibited--inhibition of the tumor cell mitotic activity took place.

Animals↗